| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Research Group for Biomolecular Medicine,* Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; the Department of Infection Biology, Hans Knoell Institute for Natural Products Research, Jena, Germany; and the Institute of Immunology and Rheumatology, The National Hospital, University of Oslo, Oslo, Norway
Porcine membranoproliferative glomerulonephritis type II in piglets of the Norwegian Yorkshire breed is considered the first animal model of human dense deposit disease. Porcine dense deposit disease is caused by the absence of the complement regulator factor H in plasma. Here we report the molecular basis for this absence. Single nucleotide exchanges at position C1590G and T3610G in the coding region of the factor H gene result in amino acid exchanges at nonframework residues L493V and I1166R that are located within SCR 9 and SCR 20, respectively. Apparently the L493V mutation represents a polymorphism whereas the I1166R causes the physiological consequences a block in protein secretion. Expression analysis shows comparable mRNA levels for factor H in liver tissue derived from both affected and healthy animals. In affected piglets, factor H protein is detected in increased amounts in liver cells. Factor H accumulates inside the hepatocytes and is not released as shown by Western blot analysis and immunohistochemistry. These data demonstrate that single amino acid exchanges of two nonframework amino acids either alone or in combination block protein secretion of factor H. This observation is also of interest for other human diseases in which factor H is involved, such as human factor H-associated form of hemolytic uremic syndrome.
This article has been cited by other articles:
 |
|
 |
|
  A.-l. Stahl, F. Vaziri-Sani, S. Heinen, A.-C. Kristoffersson, K.-H. Gydell, R. Raafat, A. Gutierrez, O. Beringer, P. F. Zipfel, and D. Karpman Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation Blood, June 1, 2008; 111(11): 5307 - 5315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J.H. Smith, J. Alexander, P. N. Barlow, M. Botto, T. L. Cassavant, H. T. Cook, S. R. de Cordoba, G. S. Hageman, T. S. Jokiranta, W. J. Kimberling, et al. New Approaches to the Treatment of Dense Deposit Disease J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2447 - 2456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Appel, H. T. Cook, G. Hageman, J. C. Jennette, M. Kashgarian, M. Kirschfink, J. D. Lambris, L. Lanning, H. U. Lutz, S. Meri, et al. Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1392 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Caprioli, F. Castelletti, S. Bucchioni, P. Bettinaglio, E. Bresin, G. Pianetti, S. Gamba, S. Brioschi, E. Daina, G. Remuzzi, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease Hum. Mol. Genet., December 15, 2003; 12(24): 3385 - 3395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Quigg Complement and the Kidney J. Immunol., October 1, 2003; 171(7): 3319 - 3324. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
